These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7542184)

  • 21. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-tryptophan syndrome: histologic features of scleroderma-like skin changes.
    Guerin SB; Schmidt JJ; Kulik JE; Golitz LE
    J Cutan Pathol; 1992 Jun; 19(3):207-11. PubMed ID: 1401345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Production of polyclonal antibodies against 1,1'-ethyliden bis[L-tryptophan] (EBT), a potential contaminant causing eosinophilia-myalgia syndrome (EMS).
    Kurihara N; Yanagisawa H; Jin Z; Wada O
    Toxicol Lett; 1993 Mar; 66(3):231-6. PubMed ID: 8475503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients.
    Kamb ML; Murphy JJ; Jones JL; Caston JC; Nederlof K; Horney LF; Swygert LA; Falk H; Kilbourne EM
    JAMA; 1992 Jan; 267(1):77-82. PubMed ID: 1727200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eosinophilia-myalgia syndrome associated with L-tryptophan. A case report with pulmonary manifestations and review of the literature.
    André M; Canon JL; Levecque P; Dermine P; Mortier C; Leveau F
    Acta Clin Belg; 1991; 46(3):178-82. PubMed ID: 1656679
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cause and pathogenesis of the eosinophilia-myalgia syndrome.
    Varga J; Uitto J; Jimenez SA
    Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simultaneous development of two cases of eosinophilia-myalgia syndrome with the same lot of L-tryptophan in Japan.
    Mizutani T; Mizutani H; Hashimoto K; Nakamura Y; Kishida M; Taniguchi H; Murata M; Kuzuhara S; Shimizu M
    J Am Acad Dermatol; 1991 Sep; 25(3):512-7. PubMed ID: 1918490
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tryptophan toxicity: a pharmacoepidemiologic review of eosinophilia-myalgia syndrome.
    Milburn DS; Myers CW
    DICP; 1991 Nov; 25(11):1259-62. PubMed ID: 1763543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-tryptophan-induced eosinophilia-myalgia syndrome. I. Report of two cases with pseudoxanthoma-elasticum-like skin changes.
    Mainetti C; Schmied E; Masouyé I; Chavaz P; Saurat JH
    Dermatologica; 1991; 183(1):57-61. PubMed ID: 1769422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eosinophilia myalgia syndrome: absence of immunoglobulin reactivity suggests a cellular rather than humoral mechanism.
    Villanova M; De Clerck LS; Cras P; Guazzi GC; Martin JJ
    Acta Neurol Belg; 1994; 94(3):200-4. PubMed ID: 7976226
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Animal models of the eosinophilia-myalgia syndrome.
    Clauw DJ
    J Rheumatol Suppl; 1996 Oct; 46():93-7; discussion 92, 97-8. PubMed ID: 8895185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathogenesis of L-tryptophan eosinophilia myalgia syndrome.
    Sternberg EM
    Adv Exp Med Biol; 1996; 398():325-30. PubMed ID: 8906284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors for developing eosinophilia myalgia syndrome among L-tryptophan users in New York.
    Back EE; Henning KJ; Kallenbach LR; Brix KA; Gunn RA; Melius JM
    J Rheumatol; 1993 Apr; 20(4):666-72. PubMed ID: 8496862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L-tryptophan and eosinophilia-myalgia syndrome.
    Shapiro S
    Lancet; 1994 Sep; 344(8925):817-9. PubMed ID: 7916094
    [No Abstract]   [Full Text] [Related]  

  • 37. Bias or biology: evaluating the epidemiologic studies of L-tryptophan and the eosinophilia-myalgia syndrome.
    Horwitz RI; Daniels SR
    J Rheumatol Suppl; 1996 Oct; 46():60-72. PubMed ID: 8895182
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak.
    Hibbs JR; Mittleman B; Hill P; Medsger TA
    Arthritis Rheum; 1992 Mar; 35(3):299-303. PubMed ID: 1536667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Elevated L-kynurenine level and its normalization by prednisolone in a patient with eosinophilia-myalgia syndrome.
    Hisatomi A; Kubota A; Ohashi M; Umeda F; Nawata H; Imamura T; Nagata T
    Fukuoka Igaku Zasshi; 1997 Jan; 88(1):11-7. PubMed ID: 9037890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. L-tryptophan and the eosinophilia-myalgia syndrome.
    Drug Ther Bull; 1990 May; 28(10):37-8. PubMed ID: 2131206
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.